Chemocentryx Soars; FDA OKs Tavneos for Vasculitis Treatment (1)

(Updates stock move)

ChemoCentryx said the U.S. Food and Drug Administration has approved Tavneos or avacopan as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The stock surges as much as 93% in premarket trading.

• Tavneos is also approved for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis (the two main forms of ANCA-associated vasculitis) in Japan
• The company expects a regulatory decision in Europe following the European Medicines Agency (EMA) review by the end of 2021

To view the source of this information, click here

--With assistance from Katrina Lewis.

To contact ...